Genome-wide meta-analysis uncovers novel loci influencing circulating leptin levels by Kilpelainen, Tuomas O. et al.
ARTICLE
Received 15 Jun 2015 | Accepted 16 Dec 2015 | Published 1 Feb 2016
Genome-wide meta-analysis uncovers novel loci
inﬂuencing circulating leptin levels
Tuomas O. Kilpela¨inen et al.#
Leptin is an adipocyte-secreted hormone, the circulating levels of which correlate closely with
overall adiposity. Although rare mutations in the leptin (LEP) gene are well known to cause
leptin deﬁciency and severe obesity, no common loci regulating circulating leptin levels have
been uncovered. Therefore, we performed a genome-wide association study (GWAS) of
circulating leptin levels from 32,161 individuals and followed up loci reaching Po106 in
19,979 additional individuals. We identify ﬁve loci robustly associated (Po5 10 8) with
leptin levels in/near LEP, SLC32A1, GCKR, CCNL1 and FTO. Although the association of the FTO
obesity locus with leptin levels is abolished by adjustment for BMI, associations of the four
other loci are independent of adiposity. The GCKR locus was found associated with multiple
metabolic traits in previous GWAS and the CCNL1 locus with birth weight. Knockdown
experiments in mouse adipose tissue explants show convincing evidence for adipogenin,
a regulator of adipocyte differentiation, as the novel causal gene in the SLC32A1 locus
inﬂuencing leptin levels. Our ﬁndings provide novel insights into the regulation of leptin
production by adipose tissue and open new avenues for examining the inﬂuence of variation
in leptin levels on adiposity and metabolic health.
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L
eptin is an adipocyte-secreted hormone that inﬂuences
long-term regulation of energy homeostasis by informing
the brain about the amount of stored body fat1,2. Circulating
leptin levels correlate closely with measures of adiposity, such as
body fat mass and body mass index (BMI)3. Yet, at any given level
of adiposity, there is substantial variation in circulating leptin
levels4, of which estimated 30–50% is explained by genetic
factors5–7.
Rare homozygous loss-of-function mutations in the
leptin-encoding gene (LEP) cause leptin deﬁciency that leads to
hyperphagia and severe obesity, which can be corrected by
exogenous leptin administration8. Leptin-deﬁcient children
are born with a normal birth weight but exhibit rapid weight
gain in the ﬁrst few months of life. They show marked
abnormalities of T-cell number and function, and have high
rates of childhood infection9. Hypothalamic hypothyroidism is
present, characterized by a low free thyroxine and high serum
thyroid-stimulating hormone levels10. Pubertal development
generally does not occur due to hypogonadotropic
hypogonadism10. Individuals heterozygous for leptin mutations
exhibit a partial leptin deﬁciency with higher body fat than
control individuals11.
Candidate gene studies, typically small in size, have reported
associations of two common variants (A19G (rs2167270,
minor allele frequency (MAF) 35%) and G2548A (rs7799039,
MAF 49%)) in the promoter or 50-untranslated region of LEP
with circulating leptin levels in the general population, but these
results are inconclusive12–16. The same LEP variants have been
studied for association with obesity, but a meta-analysis of the
published results (nA19G¼ 918 and nG2548A¼ 2,174) found no
evidence of such association17. Candidate gene studies of LEP
were published before the human genome sequence was
extensively characterized and are therefore restricted to the
variants known at that time. Furthermore, although LEP is an
obvious candidate, variants in other genes may also inﬂuence
circulating leptin levels by regulating leptin production, secretion,
clearance or response. Identiﬁcation of such leptin-regulating
genes could provide novel insights into mechanisms that regulate
energy homeostasis and neuro-endocrine function1,2.
In this study, we sought to identify genetic loci associated with
circulating leptin levels by a genome-wide meta-analysis. Given
the strong correlation between leptin and adiposity, we also
examined genome-wide associations with circulating leptin levels
adjusted for BMI, to identify loci associated with leptin levels
independent of BMI.
Results
Stage 1 genome-wide meta-analysis in 32,161 individuals. We
ﬁrst performed a meta-analysis of the results from genome-wide
associations between B2.5 million genotyped and
HapMap-imputed single-nucleotide polymorphisms (SNPs) and
circulating leptin levels, including up to 32,161 individuals of
European descent from 23 studies (Supplementary Table 1). After
logarithmic transformation that normalized the distribution of
leptin levels and adjusting for age and sex, we carried out asso-
ciation analyses within each study and subsequently
meta-analysed the study-speciﬁc results. To identify loci
associated with circulating leptin levels independently of
adiposity, we performed a meta-analysis of genome-wide
associations in which we additionally adjusted for BMI.
We also performed secondary genome-wide meta-analyses
in men (n¼ 13,363) and women (n¼ 18,698) separately, as
women generally have higher leptin levels than men, primarily
due to larger percentage of body fat and greater subcutaneous fat
storage18.
Two loci, near the LEP and SLC32A1 genes, reached
genome-wide signiﬁcance (Po5 10 8) in the BMI-adjusted
meta-analysis of men and women combined (Table 1).
To conﬁrm these associations and to identify additional
leptin-associated loci, we took forward all independent (pairwise
distance 4500 kb and r2o0.1) SNPs reaching Po10 6 with
leptin levels with or without adjustment for BMI in meta-analyses
of all individuals combined, men only or women only, for
follow-up in stage 2 (Supplementary Tables 2–4).
Stage 2 follow-up in 19,979 individuals identiﬁes ﬁve loci. We
examined the associations of the loci taken forward from stage 1
in up to 19,979 additional individuals of European descent from
13 studies (Supplementary Table 5). All studies performed the
same association analyses as described in Stage 1; that is, with and
without adjustment for BMI and in men and women
combined, as well as separately. Finally, after performing a joint
meta-analysis of the stage 1 and stage 2 results, ﬁve independent
SNPs reached genome-wide signiﬁcance (Po5 10 8) in
the combined meta-analyses of men and women (Table 1). In the
BMI-adjusted meta-analysis, we conﬁrmed genome-wide
signiﬁcant associations for the loci near LEP and SLC32A1, and
identiﬁed an additional locus in GCKR. In the BMI-unadjusted
meta-analysis, we identiﬁed two additional loci near CCNL1
and in FTO. A locus in COBLL1, previously identiﬁed for asso-
ciation with BMI-adjusted waist–hip ratio (WHRadjBMI)19, blood
triglycerides20 and risk of type 2 diabetes21, reached P¼ 1 10 6
with BMI-unadjusted leptin and P¼ 2 10 6 with
BMI-adjusted leptin levels, with the leptin-increasing allele
being associated with lower WHRadjBMI, triglycerides and risk
of type 2 diabetes.
The estimated effects of ﬁve of the six loci (in/near LEP,
SLC32A1, GCKR, CCNL1 or COBLL1) on leptin levels did not
markedly differ in magnitude between the BMI-unadjusted and
BMI-adjusted models, suggesting that these associations are not
mediated by adiposity per se (Fig. 1). In contrast, the association
between the FTO locus and leptin levels was completely abolished
after adjusting for BMI, indicating that the association with leptin
is entirely mediated by the well-established association between
FTO and BMI22 (Fig. 1).
BMI is the most commonly used index of adiposity, but it is
not a direct measure of adiposity and it does not distinguish
between lean and fat body mass. To assess whether adjustment
for a more direct measure of adiposity could enhance our ability
to identify adiposity-independent loci, we performed secondary
analyses in 13 studies that had data on both BMI and body fat
percentage assessed by dual-energy X-ray absorptiometry or
bioimpedance analysis (n¼ 18,980 or 59% of stage 1 sample).
The analysis showed no marked differences in the effect sizes
between the BMI and body fat percentage-adjusted results for the
leptin-associated LEP, SLC32A1, CCNL1, GCKR, COBLL1 and
FTO loci (Supplementary Table 6), suggesting that adjustment for
BMI as compared with a more direct measure of adiposity did not
compromise our ability to identify adiposity-independent leptin-
associated loci.
Effects on other traits and potential functional roles. We took
forward the genome-wide signiﬁcant leptin loci near LEP, near
SLC32A1, in GCKR and near CCNL1, to examine their
associations with obesity-related and metabolic traits and to more
directly assess their putative roles in the control of circulating
leptin. We also took forward the locus near COBLL1, given its
robust association with WHRadjBMI19, even though it just
missed the genome-wide signiﬁcance threshold for association
with BMI-adjusted and BMI-unadjusted leptin levels (Table 1).
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As the FTO-leptin association was completely accounted for by
FTO’s association with BMI (Fig. 1), extensively described in the
literature23, we did not include this locus in our follow-up
analyses.
To examine the associations of the identiﬁed loci with
obesity-related and metabolic traits, we performed look-ups in
the data from relevant genetic consortia (Supplementary Table 7).
To study the associations of the leptin-associated loci with the
expression of nearby genes, we performed cis-expression
quantitative trait locus (eQTL) analyses in several human tissues,
including the subcutaneous (n¼ 776) and omental fat (n¼ 742),
liver (n¼ 567), lymphocytes (n¼ 778), brain (n¼ 193) and skin
(n¼ 667) (Supplementary Table 8). We also examined the
regulatory functions of these loci by studying their enrichment
with functional genomic elements in data from the Roadmap
Epigenomics Project24. Finally, to identify the causal genes in the
leptin-associated loci, we performed ex vivo knockdown studies of
adipocyte-expressed genes using small interfering RNA (siRNA)
in explanted mouse adipose tissue.
Common variation near LEP regulates leptin levels. The
rs10487505 variant (MAF 49%) is located 21 kb from LEP
(Fig. 2a) and is in modest linkage disequilibrium (LD) (r2¼ 0.4,
D0 ¼ 0.8) with the A19G (rs2167270, MAF 35%) variant that has
been extensively studied in candidate gene studies but whose
associations with increased levels of leptin and obesity have been
inconclusive13,16. The leptin-increasing allele of the rs10487505
variant has been nominally associated with weight regain after
bariatric surgery in a candidate gene-based analysis of 1,443
patients25. Look-ups in consortium data showed a nominally
signiﬁcant association for the leptin-decreasing allele of
rs10487505 with higher BMI in the GIANT Consortium
(P¼ 0.03, N¼ 221,677), as well as with increased risk of early-
onset obesity (P¼ 0.04, N¼ 13,848) and higher birth weight
(P¼ 0.02, N¼ 26,836) in the EGG Consortium (Supplementary
Table 7). Although LEP is an obvious candidate gene to
account for the association with circulating leptin levels, the
rs10487505 variant was not associated with LEP messenger RNA
expression in the omental or subcutaneous adipose tissue
(SCAT), liver, lymphocytes, brain or skin (Supplementary
Tables 8 and 9).
A variant in strong LD with rs10487505 (rs6979832, r2¼ 0.98)
overlapped with predicted enhancer elements in all three adipose
cell lines of the Roadmap Epigenomics Project24. Further, a
previous study identiﬁed a 465-bp adipocyte-speciﬁc enhancer
region 4.5 kb upstream from the LEP transcription start site by
using luciferase assays and chromatin state mapping26. This
region harbours rs10249476 that is in modest LD with
rs10487505 (r2¼ 0.4, D0 ¼ 0.8) and reached the second most
signiﬁcant association with BMI-adjusted leptin levels in stage 1
meta-analysis (P¼ 3 10 10; n¼ 30,810) (Fig. 2a).
Collectively, although the locus near LEP overlaps with
predicted enhancer elements, the lack of association with LEP
transcript expression in the fasting state suggests that other
mechanisms may be involved in mediating the association of this
locus with leptin levels, such as an effect on LEP expression in the
fed state27 or an effect on leptin protein secretion.
To validate our knockdown strategy for subsequent analyses of
candidate genes in loci other than the locus near LEP, we used
siRNA against Lep in mouse adipose tissue explants.
Electroporation of the perigonadal adipose tissue (PGAT)
explants with siRNA against Lep resulted in a 92% decrease in
Lep mRNA (Po1 10 4) and a 92% decrease in secreted leptin
(P¼ 4 10 4) (Fig. 4a,b, Supplementary Fig. 1C,D and
Supplementary Table 10). In addition, to determine whether
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Figure 1 | Meta-analysis results for the leptin-associated loci. The bars show the additive effect of the loci in or near LEP, GCKR, CCNL1, SLC32A1, COBLL1
and FTO on BMI-unadjusted and BMI-adjusted leptin levels in the meta-analysis of Stage 1 and Stage 2 combined. The error bars indicate s.e.
Table 1 | Meta-analysis results in men and women combined for the genome-wide signiﬁcant leptin-associated loci and for the
locus in COBLL1.
SNP Nearest gene Chr:Position Effect/other allele EAF Leptin unadjusted for BMI Leptin adjusted for BMI
Stage 1 Stage 2 Stage 1þ 2 Stage 1 Stage 2 Stage 1þ 2
P I2 N P I2 N b s.e. P N P I2 N P I2 N b s.e. P N
rs10487505 LEP 7:127647399 G/C 0.5 3.97E06 0% 29470 1.98E01 0% 17110 0.023 0.005 9.00E06 46580 2.70E 11 0% 29255 5.22E03 0% 16781 0.029 0.004 1.99E 12 46036
rs780093 GCKR 2:27596107 C/T 0.61 1.82E07 28% 32147 3.64E04 32% 19979 0.032 0.005 2.33E 10 52126 6.30E07 35% 31802 1.37E04 43% 19648 0.024 0.004 3.80E 10 51450
rs900400 CCNL1 3:158281469 T/C 0.6 7.31E07 42% 32128 1.66E03 0% 19685 0.03 0.005 5.60E09 51813 9.77E07 42% 31785 1.67E02 0% 19354 0.021 0.004 1.17E 7 51139
rs6071166 SLC32A1 20:36766426 C/A 0.37 2.03E07 1% 29471 1.61E01 0% 17007 0.027 0.006 6.56E07 46478 2.86E08 0% 29256 3.93E02 0% 16678 0.024 0.004 1.75E08 45934
rs6738627 COBLL1 2:165252696 A/G 0.37 8.26E07 0% 25573 8.59E02 0% 19573 0.027 0.006 1.41E06 45146 4.57E06 4% 25229 4.53E02 0% 19242 0.02 0.004 1.92E06 44471
rs8043757 FTO 16:52370951 T/A 0.4 8.75E08 0% 32120 2.71‘E03 15% 19919 0.03 0.005 1.13E09 52039 6.05E01 8% 31776 7.48E01 39% 19588 0.001 0.004 8.35E01 51364
BMI, body mass index; EAF, effect allele frequency; SNP, single-nucleotide polymorphism.
Leptin (mgml 1) was logarithmically transformed. The study-speciﬁc analyses were performed with linear regression models, while accounting for sex, age and age2. Meta-analyses of the study-speciﬁc
results were performed using ﬁxed effects meta-analysis. B refers to the change in logarithmically transformed leptin per each copy of the effect allele.
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electroporation with siRNA altered other secretory function(s) of
the perigonadal explants, we measured secretion of adiponectin
and found no changes associated with Lep knockdown (Fig. 4d
and Supplementary Fig. 1E).
ADIG may regulate leptin expression. The intergenic rs6071166
variant, B20 kb from the SLC32A1 gene (Fig. 2c), reached gen-
ome-wide signiﬁcance for association with BMI-adjusted leptin
levels and has not been previously identiﬁed for association with
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any other traits. In look-ups of genome-wide association study
(GWAS) consortium data, we did not ﬁnd signiﬁcant association
with other obesity-related or metabolic traits (Supplementary
Table 7). The rs6071166 variant was not associated with the
mRNA expression of nearby genes in the adipose tissue, liver,
lymphocytes, brain or skin (Supplementary Tables 8 and 9).
To identify the potential causal gene in this locus using the
mouse PGAT explant model described above, we ﬁrst measured
the expression levels of murine homologues of genes surrounding
the lead variant associated with circulating leptin levels. We tested
PGAT and SCAT of 4-month-old C57BL/6J mice fed chow or
high-fat diet (Fig. 3c,d). In addition, we analysed candidate gene
expression in other tissues (liver and hypothalamus) that we
predicted could play a role in circulating leptin levels via effects
on leptin clearance or response (Supplementary Fig. 7). Genes
were considered strong candidates if they were highly expressed
in adipose tissue and/or if they were regulated by high-fat diet
feeding in a manner similar to Lep. This analysis identiﬁed
adipogenin (Adig) as a candidate gene in the SLC32A1 locus; Adig
is highly expressed in the adipose tissue, in contrast to other
nearby genes. To test whether Adig affected Lep expression, we
performed ex vivo knockdown studies using siRNA against Adig
in mouse PGAT explants. We found that knockdown of Adig
decreased Lep expression by 26% (P¼ 4 10 4) and leptin
secretion by 23% (P¼ 0.003), consistent with a causal role for
ADIG in control of circulating leptin levels (Fig. 4a,b and
Supplementary Fig. 2C,D).
ADIG is located B116 kb from the rs6071166 variant and
encodes a cytoplasmic adipocyte protein adipogenin, that is,
similar to leptin, highly and speciﬁcally expressed in the adipose
tissue28–30 and upregulated by treatment with insulin and
glucose30. Adig expression is also strongly upregulated in
murine 3T3-L1 preadipocytes during in vitro differentiation
into adipocytes28,29. Two studies have investigated the effect of
Adig knockdown on the differentiation of 3T3-L1 cells and
expression of Pparg2, a master regulator of adipocyte
differentiation, but with conﬂicting results; whereas the ﬁrst
study found Adig knockdown to block adipocyte differentiation
and decrease Pparg2 expression28, a later study found no similar
changes30. When we measured Pparg2 expression following Adig
knockdown in PGAT explants containing mature adipocytes, we
did not see a change as compared with controls (Supplementary
Fig. 2F).
Common variation in GCKR regulates leptin levels. Variants
(r2Z0.9 with our lead SNP rs780093) of the leptin-associated
locus in GCKR have previously shown genome-wide signiﬁcant
associations with more than 25 metabolic traits; the leptin-
increasing allele has been associated with increased fasting glu-
cose and fasting insulin but decreased 2-h glucose and higher
high-density lipoprotein cholesterol, and lower total cholesterol,
low-density lipoprotein cholesterol, triglycerides, C-reactive
protein and circulating uric acid levels, among others
(Supplementary Table 11). The GCKR gene encodes a regulatory
protein in the liver that inhibits the activity of glucokinase, the
enzyme responsible for regulating the uptake, metabolism and
storage of circulating glucose31. A putative causal variant in this
gene is the common nonsynonymous Pro446Leu variant
(rs1260326), for which rs780093 acts as a good proxy (r2¼ 0.9).
Carriers of the glucose-lowering Leu allele have a reduced ability
to sequester and inhibit glucokinase and a blunted response to
fructose 6-phosphate, both of which favour the generation of free
and active cytoplasmic glucokinase32.
The mechanisms that might link changes in GCKR function to
leptin levels are not known. As insulin increases leptin secretion
from adipocytes33 and the GCKR locus is strongly associated with
circulating levels of insulin34, the association of the GCKR locus
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Figure 3 | Expression of murine homologues of genes. Expression of murine homologues of genes located within Lep (a,b), Slc32a1 (c,d), Gckr (e,f), Ccnl1
(g,h) and Cobll1 loci (i,j) in PGAT and SCAT from 4-month-old mice fed chow (black bars) or high-fat diet (HFD; grey bars). Quantitative PCR (qPCR)
transcripts were normalized using ActB, Rplp0, Gapdh and Ppia as housekeeping genes. N¼ 5 mice per group. T-test. *Po0.05, **Po0.01 and ***Po0.001.
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with leptin levels could be the consequence of the GCKR locus’
effect on insulin levels. The leptin-increasing allele of the
rs780093 variant was signiﬁcantly associated with higher levels
of fasting insulin in studies included in our stage 2 meta-analyses
(P¼ 2 10 5, N¼ 8,953). To test whether insulin mediated the
association of rs780093 with circulating leptin levels, we analysed
the association of rs780093 with leptin, while adjusting for fasting
insulin levels. Although the effect size was somewhat attenuated,
the association of rs780093 with BMI-adjusted leptin levels
remained signiﬁcant after adjustment for fasting insulin
(b¼ 0.047, P¼ 2 10 4 versus b¼ 0.034, P¼ 0.004 before and
after the adjustment, respectively), suggesting that the association
of the GCKR locus with leptin is at least in part independent of
effects on insulin levels.
Although GCKR’s function renders it a potential candidate
among the genes in this region, cis-eQTL analyses showed
association of the leptin-increasing allele of rs780093 with
increased expression of the nearby IFT172 in the liver
(P¼ 7 10 30), omental fat (P¼ 6 10 64) and subcutaneous
fat (P¼ 3 10 52) (Supplementary Table 9). The rs780093
variant is, however, only in moderate LD (r2¼ 0.4) with the peak
SNP inﬂuencing IFT172 expression in the region and the peak
SNP remained signiﬁcantly associated with IFT172 expression
after adjustment for rs780093, whereas the association of
rs780093 was abolished after adjustment for the peak SNP
(Supplementary Table 9).
Because of the observations in human tissues, we examined
Ift172 in the mouse explant model. Ift172 was not highly
expressed in mouse PGAT or SCAT and levels were not
upregulated by high-fat diet (Fig. 3e,f). Ift172 was, however,
upregulated in the liver under high-fat diet feeding
(Supplementary Fig. 7E). Knockdown of Ift172 in PGAT explants
decreased Lep mRNA expression by 22% (P¼ 0.02), but did not
decrease leptin protein secretion (P¼ 0.6) (Fig. 4a,b and
Supplementary Fig. 3C,D). IFT172 is known to play a major role
in assembly and maintenance of primary cilia that act as critical
signalling hubs for cellular pathways during development35.
Knockout of Ift genes in central neurons causes obesity in mice36
and obesity is a clinical feature in two human ciliopathic
syndromes, the Alstro¨m and Bardet–Biedl syndromes37,38. In the
hypothalamus, alterations in the function of the primary cilium
lead to impaired leptin signalling39. Therefore, we cannot exclude
a role for IFT172 in the regulation of circulating leptin levels.
Another nearby gene, MpV17 mitochondrial inner membrane
protein, is a potential candidate in the region based on its
expression in mice fed chow or high-fat diet; Mpv17 expression
was increased by high-fat diet, in a manner similar to Lep
(Fig. 3c,d). However, knockdown of Mpv17 did not change Lep
mRNA expression (P¼ 0.2) or leptin secretion (P¼ 0.2) by
PGAT explants (Fig. 4a,b and Supplementary Fig. 4C,D),
suggesting that the involvement of MPV17 in leptin regulation
is unlikely.
Locus near CCNL1 regulates leptin levels and birth weight. The
leptin-decreasing allele of rs900400, located 67 kb upstream from
CCNL1 (Fig. 2d), was previously reported for its association with
lower birth weight40. This cross-phenotype association could
indicate a mechanism that is shared between birth weight and
leptin levels in adulthood. Fetal adipose tissue is capable of
producing leptin41 and fetal leptin levels are correlated with fetal
fat mass42,43. Placenta provides an additional source of leptin for
the fetus, however, and it has been suggested that leptin could
mediate fetal growth44,45. Assuming that leptin levels track from
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Figure 4 | Candidate gene knockdown studies in PGATexplants. Changes in Lep mRNA expression (a) and secretion into media (b) following candidate
gene knockdown in PGATexplants following stimulation with insulin and dexamethasone for 12 h. Gene expression induced by stimulation with insulin and
dexamethasone (c) N¼ 5–13 mice per group (3 replicates/condition/mouse). Secreted adiponectin was measured as a control for non-leptin secretory
function (d) N¼ 5 mice per group. Two-way repeated measures analysis of variance (ANOVA). *Po0.05, **Po0.01, ***Po0.001 and ****Po0.0001.
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birth through adulthood, increased leptin levels could drive the
association of the CCNL1 locus with birth weight. Other studies
suggest that leptin production is decreased in cultured adipocytes
from men born with a low birth weight46. Therefore, the
association of the CCNL1 locus with leptin levels in adulthood
could be mediated by its association with birth weight.
Although CCNL1 is the nearest gene to rs900400, our cis-eQTL
analyses identiﬁed rs900400 as the variant most signiﬁcantly
associated with the expression of another nearby gene, TIPARP
(Supplementary Table 9). The TIPARP gene encodes a poly
(ADP-ribose) polymerase involved in DNA repair. The leptin-
increasing allele of rs900400 was associated with lower TIPARP
expression in omental fat (3 10 30) and subcutaneous fat
(P¼ 7 10 58) (Supplementary Table 9). Tiparp was also
implicated as a causal gene by our expression analysis of mouse
adipose tissue and its expression was increased in SCAT and liver
in mice fed with high-fat diet (Fig. 3h and Supplementary
Fig. 7G). Knockdown of Tiparp in mouse PGAT explants did not,
however, signiﬁcantly alter the expression of Lep mRNA (P¼ 0.7)
or leptin secretion (P¼ 0.8) (Fig. 4a,b and Supplementary
Fig. 5D,E). Although we attempted to use SCAT for
explant knockdown studies, high intra-depot variability
compromised this approach. Interestingly, stimulation of the
explants with insulin and dexamethasone increased explant
expression of Tiparp by 50% (P¼ 0.003) over incubation in basal
media alone, in a manner similar to Lep expression (Fig. 4c and
Supplementary Fig. 5A). Collectively, although TIPARP remains a
putative causal gene within the locus near CCNL1, further
evidence is required to conﬁrm its role in the regulation of
circulating leptin levels.
COBLL1 or GRB14 may regulate leptin levels. The intronic
rs6738627 variant in COBLL1 (Fig. 2e) did not reach genome-
wide signiﬁcance for the association with leptin levels (Fig. 1 and
Table 1). However, as previous GWAS have shown robust asso-
ciations of the leptin-increasing allele with a lower WHRadjBMI19,
we chose to take it forward for follow-up analyses, to examine the
role of leptin levels in the previous associations.
Look-ups in data from genetic consortia showed a strong
association of the leptin-increasing allele of rs6738627 with
higher body fat percentage (P¼ 2 10 8, n¼ 76,338;
Supplementary Table 7). As reported previously, the rs6738627
variant was also strongly associated with decreased WHRadjBMI
(P¼ 2 10 8, n¼ 174,672; Supplementary Table 7), suggestive
of a preferential gluteal rather than abdominal fat storage, which
may contribute to the association of rs6738627 with increased
leptin levels47.
In PGAT and SCAT expression analyses in mice, we found an
upregulation of Cobll1 in high-fat diet-fed mice in both depots
(Fig. 3i,j). Although knockdown of Cobll1 in the perigonadal
explants did not inﬂuence Lep mRNA expression (P¼ 0.2), it did
decrease leptin protein secretion by 16% (P¼ 3 10 4,
Fig. 4a,b), suggesting a potential causal role for Cobll1. In
addition, stimulation of explants with insulin and dexamethasone
increased explant expression of Cobll1 by 78% (P¼ 0.004) over
incubation in basal media alone (Fig. 4c and Supplementary
Fig. 6A). COBLL1 is known to be involved in neural tube
formation48, but its possible functions in adipose tissue are
unknown.
In human eQTL analyses, the leptin-increasing allele of the
COBLL1 locus showed an association with lower expression of
GRB14 in omental fat (P¼ 5 10 12) and subcutaneous fat
(P¼ 3 10 5) (Supplementary Table 9). We did not, however,
ﬁnd high expression of Grb14 in PGAT or SCAT explants from
mice and the levels were not regulated by high-fat diet feeding
(Fig. 3i,j). The protein product of GRB14 is the growth factor
receptor-bound protein 14 that binds directly to the insulin
receptor and inhibits insulin signalling49. The adipose tissue
expression of GRB14 may play a role in regulating insulin
sensitivity50. Grb14-deﬁcient mice exhibit improved glucose
tolerance, lower circulating insulin levels and increased
incorporation of glucose into glycogen in the liver and skeletal
muscle51. Both COBLL1 and GRB14 are thus possible candidates
to account for the association of the COBLL1 locus with leptin
levels.
Enrichment with pathways and regulatory elements. We used
the Data-driven Expression Prioritized Integration for Complex
Traits (DEPICT) software52 to identify enrichment of gene sets
and pathways across loci reaching Po1 10 5 for association
with leptin levels. However, none of our ﬁndings reached the false
discovery rate threshold of 5% (Supplementary Tables 12–17).
Next, we used the Gene Relationships Across Implicated traits
(GRAIL) tool53 to identify genes near the leptin-associated loci
having similarities in the text describing them within published
article abstracts. However, no statistically signiﬁcant results were
found in these analyses either (Supplementary Tables 18 and 19).
Finally, we used the Uncovering Enrichment Through Simulation
method54 to test for the overall enrichment of leptin-associated
loci reaching Po10 5 with ChromHMM annotations for adipose
and brain tissues available from the Roadmap Epigenomics
Project24. However, we did not ﬁnd signiﬁcant enrichment of
our leptin-associated loci in any chromatin states once corrected
for multiple testing (Supplementary Table 20). The lack of
signiﬁcant ﬁndings may be due to the small number of loci
identiﬁed and the limited knowledge available on leptin-regulating
pathways in adipose tissue.
Established adiposity loci and leptin. Circulating leptin levels
correlate closely with BMI and other measures of adiposity3. The
most recent GWAS meta-analysis for BMI, including nearly
340,000 individuals, identiﬁed 97 loci that reached genome-wide
signiﬁcance22. Of the 97 BMI-increasing loci, 89 showed a
directionally concordant association with increased
BMI-unadjusted leptin levels (Pbinomal¼ 2 10 18), of which
25 reached nominal signiﬁcance (Supplementary Table 21).
Previous GWAS of extreme and early-onset obesity have
identiﬁed 12 genome-wide signiﬁcant loci55–58. Of these,
ten showed a directionally consistent association with
increased BMI-unadjusted leptin levels (Pbinomal¼ 0.04), of
which ﬁve reached nominal signiﬁcance (Supplementary
Table 21).
We also examined leptin associations for 49 loci identiﬁed in
GWAS for WHRadjBMI, a measure of body fat distribution
independent of overall adiposity19. Of the 49 WHRadjBMI-
increasing loci, only 24 showed a directionally concordant
association with increased BMI-adjusted leptin levels
(Supplementary Table 22). As the distribution of body fat
differs between men and women, we also examined the leptin
associations for the 49 WHRadjBMI loci in men and women
separately. There was no enrichment of leptin associations in
either of the sexes, with 27 loci showing a directionally
concordant association with increased leptin levels in men and
20 loci in women (Supplementary Table 22).
Discussion
In a meta-analysis of genetic association data in up to 52,126
individuals, we identiﬁed 5 common loci associated with
circulating leptin levels. In addition, a locus near COBLL1,
previously identiﬁed for association with a lower WHRadjBMI19,
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reached P¼ 1 10 6 for association with increased leptin levels.
Even though leptin correlates strongly with adiposity, we did not
identify loci previously associated with BMI, other than FTO,
despite having a sample size similar to early GWAS meta-analyses
of BMI that identiﬁed multiple loci59. On the contrary, ﬁve of the
six loci we identiﬁed were associated with leptin independently of
BMI or body fat percentage. Our ﬁndings indicate that genetic
mechanisms not inﬂuencing adiposity may have an important
role in the regulation of circulating leptin levels.
Our strongest adiposity-independent leptin signal was near
LEP, but we also identiﬁed leptin-associated variants in four other
genomic loci, providing evidence that mechanisms other than
those that involve LEP per se may regulate leptin production and
release from adipose tissue. In one of these loci, near SLC32A1,
our knockdown studies indicated a role for adipogenin, a gene
involved in the regulation of adipocyte differentiation28,29.
Although adipogenin was identiﬁed as a potent regulator of
adipogenesis a decade ago28,29, our results provide the ﬁrst
evidence linking this function to leptin regulation. We anticipate
that our ﬁndings will motivate and inform eventual testing of
Adig by transgenic manipulation in mice.
No clear effect on leptin production was seen following
knockdown of candidate genes in the GCKR and CCNL1 loci,
which may indicate that the gene implicated by position plays no
role in the phenotype, or that the effect was undetectable in our
experimental conditions. Alternatively, the association with leptin
levels may be explained by effects of non-coding elements on
other genes outside the implicated genetic interval, or by inter-
species differences. Furthermore, although adipose tissue is the
most direct contributor to circulating leptin levels, the effect of
the causal gene may be conveyed by another tissue; leptin
production and secretion are inﬂuenced by insulin, catechola-
mines and other hormones, as well as paracrine effects of local
inﬂammatory cells on adipocytes60.
Although the locus near SLC32A1 had not been identiﬁed
previously for association with other traits, the leptin-associated
loci in/near GCKR, CCNL1 and COBLL1 have been associated
with multiple obesity-related and metabolic traits19,20,34,40,61.
These cross-phenotype associations may either reﬂect pleiotropy,
where a gene product inﬂuences multiple traits, and/or mediation
effects, where one phenotype is causally related to a second
phenotype. For example, the association of the pleiotropic GCKR
locus with leptin levels may be partly mediated through GCKR’s
role in the regulation of glucose homeostasis and insulin
levels34,61, which may inﬂuence leptin production and secretion
in adipose tissue33. The COBLL1 locus is strongly associated with
decreased WHRadjBMI, indicative of a preferential accumulation
of gluteal subcutaneous fat, which may contribute to the
observed association with circulating leptin levels47. The
identiﬁcation of the birth weight locus, CCNL1, as a
leptin-regulating locus may provide an intriguing link between
leptin regulation and fetal growth, albeit such a link remains to be
more ﬁrmly established45.
Unravelling the polygenic basis of leptin production could
provide opportunities for targeted leptin supplementation in
obese individuals. Although leptin therapy is an efﬁcient weight-
loss treatment for obese individuals with congenital leptin
deﬁciency, the beneﬁcial effects of leptin supplementation do
not translate to all obese patients62. Sensitivity to changes in
circulating concentration of leptin may be enhanced at very low
values11 where a relatively small increase in leptin production
may be sensed by the homeostatic feedback system that controls
energy balance. As a substantial minority of individuals with
common forms of obesity, not associated with leptin mutations,
have relatively low levels of circulating leptin63, augmenting
leptin levels in this subgroup could be therapeutically worthwhile.
Identiﬁcation of leptin-regulating loci may provide new tools for
identifying obese individuals with susceptibility to low leptin
levels and who may beneﬁt of leptin treatment.
In 2010, Sun et al.64 identiﬁed two common non-synonymous
SNPs in the leptin receptor (LEPR) gene associated with leptin
receptor levels. Leptin receptor plays an essential role in
mediating the physiological effects of leptin. Although some
studies have described abnormally high circulating leptin levels in
carriers of rare LEPR mutations65, others have not66. We did not
ﬁnd association between LEPR variants and circulating leptin
levels, suggesting that common variants in LEPR are not
important regulators of circulating leptin levels.
Our meta-analyses were limited by the number of available
studies with leptin data, imputation by HapMap reference panel
for autosomal chromosomes and the fact that we examined
additive effects only. In addition, we corrected for adiposity by
adjusting for BMI, which is a heterogeneous measure of adiposity
as it does not account for individual differences in body fat and
lean mass. Future discovery efforts in extended sample sizes based
on genome-wide imputation of 1000 Genomes reference panels,
which include X and Y chromosomes and which also test for
recessive and dominant inheritance, will allow for the discovery of
more and lower-frequency variants, and for reﬁning association
signatures of already established leptin-associated loci.
In summary, we identiﬁed six genetic loci associated with
circulating leptin levels, of which ﬁve showed associations
independently of adiposity. Our ﬁndings represent a step forward
in the understanding of biological mechanisms regulating leptin
production in adipose tissue and open new avenues for
examining the inﬂuence of variation in leptin levels on adiposity
and metabolic health.
Methods
Main analyses
Study design. We conducted a two-stage meta-analysis to identify leptin-associated
loci in adults of European ancestry. In stage 1, we performed a meta-analysis of 23
GWAS (n¼ 32,161) (Supplementary Table 1) for BMI-unadjusted and BMI-
adjusted circulating levels of leptin. Stage 2 included 13 additional studies
(n¼ 19,979), which provided either de novo or in silico data for the lead SNPs of
the independent loci reaching Po1 10 6 in Stage 1 (Supplementary Table 5).
Secondary meta-analyses were conducted in men (n¼ 13,363) and women
(n¼ 18,698) separately, and with adjustment for body fat percentage (assessed by
dual-energy X-ray absorptiometry or bioimpedance analysis) instead of BMI
(n¼ 18,980). The study-speciﬁc descriptive statistics are presented in
Supplementary Table 23.
Stage 1 genome-wide association analyses. Following study-speciﬁc quality
control measures, the genotype data were imputed using the HapMap Phase II
CEU reference panel (Supplementary Table 24). Directly genotyped and imputed
variants were then tested for association with logarithmically transformed leptin
(ngml 1), adjusting for age, age2 and any necessary study-speciﬁc covariates (for
example, genotype-derived principal components) in a linear regression model.
The analyses were performed with and without additional adjustment for BMI. In
studies that had assessed body fat percentage with bioimpedance analysis or dual-
energy X-ray absorptiometry, additional analyses were performed with adjustment
for body fat percentage. The analyses were performed in men and women
separately. In studies that included closely related individuals, regression
coefﬁcients were also estimated in the context of a variance component model that
modelled relatedness in men and women combined, with sex as a covariate.
Before performing meta-analyses on the data from individual studies, SNPs
with poor imputation quality scores (r2-hat o0.3 in MACH, proper-info o0.4 in
IMPUTE, INFO o0.8 in PLINK) or with a minor allele count o6 were excluded
for each study (Supplementary Table 24). The genotype data for the
leptin-associated lead SNPs was of high quality with a median imputation score of
Z0.94 (Supplementary Table 26). The ﬁfth percentile for all SNPs was Z0.80,
except for the previously established rs900400 SNP near CCNL1.
All individual GWAS were genomic control corrected before meta-analyses.
Individual study-speciﬁc genomic control values ranged from 0.977 to 1.051.
Fixed effects meta-analyses were then conducted using the inverse variance-
weighted method implemented in METAL. The genomic control values for the
meta-analysed results were 1.050, 1.026 and 1.022 in the BMI-unadjusted
meta-analyses of all individuals, men and women, and 1.046, 1.022 and 1.015 in the
BMI-adjusted meta-analyses, respectively. Using the LD score regression method67
in the Stage 1 meta-analyses suggests that the observed inﬂation is not due to
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population substructure. The regression intercept, which estimates inﬂation after
removing polygenic signals, was 0.994 for BMI-unadjusted and 1.004 for
BMI-adjusted meta-analyses of men and women combined.
Selection of SNPs for follow-up. We used a pairwise distance criterion of
±500 kb and r2o0.1 between SNPs that reached Po10 6 in the meta-analysis of
BMI-adjusted or -unadjusted meta-analysis of leptin levels in Stage 1 in men and
women combined or separately, to select loci forward for follow-up in Stage 2. We
tested the association of the lead SNPs in up to 19,929 adults of white European
ancestry in Stage 2.
Stage 2 follow-up of the loci reaching Po10 6 in Stage 1. Association results
were obtained from 13 studies that had not been included in the Stage 1
meta-analyses (Supplementary Table 5). Samples and SNPs that did not meet the
quality control criteria deﬁned by each individual study were excluded. Minimum
genotyping quality control criteria were deﬁned as Hardy–Weinberg equilibrium
P410 7, call rate490% and concordance499% in duplicate samples in each of
the follow-up studies.
We tested the association between the SNPs and leptin in each Stage 2 study
using approaches similar to those described for the Stage 1 studies. We
subsequently performed a meta-analysis of b-coefﬁcients and s.e. from Stage 2
using the inverse variance ﬁxed effects method. The ﬁnal meta-analysis combined
GWAS results from Stage 1 with the Stage 2 results. The conventional
P-value threshold of o5 10 8 in the combined Stage 1 and Stage 2
meta-analysis was used to determine genome-wide signiﬁcance.
Identifying genes and biological pathways at associated loci
Cross-trait look-ups. To further examine the relationship between the leptin-
associated loci and anthropometric and metabolic parameters, we acquired asso-
ciation results for the loci in or near LEP, SLC32A1, GCKR, CCNL1 and COBLL1
from nine GWAS meta-analysis consortia: ADIPOGen (BMI-adjusted adipo-
nectin), BCGC (body fat percentage), DIAGRAM (type 2 diabetes), Early growth
genetics (birth weight, early-onset obesity), ICBP (systolic and diastolic blood
pressure), GIANT (height, BMI, waist–hip ratio adjusted for BMI), GLGC
(circulating levels of high-density lipoprotein cholesterol, low-density lipoprotein
cholesterol, triglycerides and total cholesterol), MAGIC (fasting glucose, fasting
insulin) and ReproGen (age at menarche) (Supplementary Table 7).
National Human Genome Research Institute GWAS Catalog look-ups. To
identify the associations of the leptin-associated loci in published GWAS, we
extracted previously reported GWAS associations within 500 kb and r240.7 with
any of the lead leptin-associated SNPs, from the GWAS Catalog of the National
Human Genome Research Institute (www.genome.gov/gwastudies)
(Supplementary Table 11).
Overlap with functional regulatory elements. We used the Uncovering
Enrichment Through Simulation method to combine the leptin association data
with the Roadmap Epigenomics Project segmentation data54. The pipeline chose
10,000 sets of random SNPs among HapMap2 SNPs with a MAF40.05 and that
matched the original input SNPs based on proximity to a transcription start site
and the number of LD partners (r240.8 in individuals of European ancestry in the
1000 Genomes Project). The LD partners were combined with their original lead
SNP to create 10,000 sets of matched random SNPs and their respective LD
partners. These sets were intersected with the 15-state ChromHMM data from the
Roadmap Epigenomics Project and resultant co-localizations were collapsed from
total SNPs down to loci, which were then used to calculate an empirical P-value
when comparing the original SNPs with the random sets. In addition to examining
overall enrichment for all leptin-associated loci combined, we examined the
variant-speciﬁc overlap with regulatory elements for each of the leptin-associated
index SNPs and variants in strong LD (r240.8).
Expression quantitative trait loci. We examined the cis-associations of the
leptin-associated loci with the expression of nearby genes in the lymphocytes, skin,
liver, omental fat, subcutaneous fat and brain tissue (Supplementary Table 8).
Conditional analyses were performed by including both the leptin-associated SNP
and the most signiﬁcant cis-associated SNP in the association model for a given
transcript. To minimize the potential for false positives, we only considered
associations that reached study-speciﬁc Bonferroni-corrected signiﬁcance threshold
(Po0.05/(total number of transcripts tested)).
Pathway analyses
GRAIL analyses: We used GRAIL to identify genes near the leptin-associated loci
having similarities in the published scientiﬁc text using PubMed abstracts as of
December 2006 (ref. 53). The leptin loci were queried against HapMap release 22
for the European panel and we controlled for gene size.
DEPICT analyses: We used DEPICT to identify the most probable causal gene
at a given associated locus, reconstituted gene sets enriched for BMI associations,
and tissues and cell types in which genes from associated loci are highly
expressed52. We clumped GWAS-based meta-analysis summary statistics using
500 kb ﬂanking regions, LD r240.1 and excluded SNPs with PZ1 10 5.
HapMap Project Phase II CEU genotype data were used to compute LD and
genomic coordinates were deﬁned by genome build GRCh37.
Knockdown of genes in mouse adipose tissue explants
Materials. Expression analyses were performed on PGAT and SCAT from
4-month-old C57BL/6J mice (derived from Jackson, Stock number 000664) fed
chow (Purina PicoLab 5058) or high-fat diet (Research Diets, Inc., D12492i, 60%
kcal from fat), to increase adiposity and circulating leptin levels. We measured
expression of genes located ±100 kb of each lead variant or genes including SNPs
with r240.4 with the lead variant. Tiparp was included after its identiﬁcation by
eQTL analysis, and Ucn and Mpv17 were included based on their proximity to
variants with r240.4 with the lead variant.
For knockdown experiments, 15-week-old male C57BL/6J mice fed high-fat diet
ad libitum starting at 6 weeks of age were purchased from Jackson Laboratory
(Stock Number 380050, Bar Harbor, ME). Animals were maintained at Columbia
University animal facility for up to an additional 5 weeks until they reachedB30%
fat mass as determined by time-domain NMR (Minispec Analyst AD; Bruker
Optics, Silberstreifen, Germany).
Mice were maintained at an ambient temperature of 22 C–24 C with a 12-h
dark–light cycle (lights on at 0700 h) in a pathogen-free barrier facility. The
protocol was approved by the Columbia University Institutional Animal Care and
Use Committee.
Electroporation and culture of adipose tissue explants. Non-fasted mice were
killed at around 20 weeks of age atB1000 h. PGAT was dissected and minced into
1- to 2-mm fragments. These fragments were evenly distributed into three
replicates per control or knockdown condition. Approximately 7–11 fragments
were added per well (for a total amount of B80mg tissue) in
12-well culture dishes containing 1ml M199 with Antibiotic-Antimycotic (Anti-
Anti, 5 ; Invitrogen). Following a 20-min incubation in 5 Anti-Anti media,
tissue fragments were washed twice with 1ml PBS and then transferred to 4mm
Gene Pulser cuvettes (Bio-Rad) and electroporated in 400 ml PBS with 1 nmol
siRNA against Lep, Adig, Ift172, Mpv17, Tiparp or Cobll1 (Stealth siRNA,
Invitrogen). Non-targeting sequences were used as negative controls (Invitrogen).
Electroporation was performed with a Gene Pulser XceII (Bio-Rad) using
50V, 102 wave pulses, with a pulse length of 30ms and 0.1ms between pulses68.
The tissue fragments were subsequently cultured at 37 C in 5% CO2 in 12-well
plates for 20 h in basal media consisting of M199 media with 10% fetal bovine
serum (Invitrogen) plus 1 Anti-Anti before stimulation for 12 h with basal media
plus 7 nM insulin and 25 nM dexamethasone (both from Sigma), to maintain leptin
expression in the explants at levels comparable to those of in vivo tissues69.
Knockdown was considered successful if candidate expression was decreased by
Z30%. The effect of insulin and dexamethasone on expression of candidate genes
was determined using the same mincing and culturing strategy without
electroporation.
Measuring mRNA levels and leptin and adiponectin secretion. Total RNA was
isolated using TRIzol reagent (Invitrogen) and reverse transcribed using
Transcriptor First Strand cDNA Synthesis Kit (Roche) using both OligoDT and
random hexamer primers. Lightcycler 480 SYBR Green I Master was used for
quantitative PCR assays (Roche). Expression of murine homologues of candidate
genes in PGAT and SCAT was determined using the 2(DDC(T)) method70.
Gene expression in the knockdown experiments was calculated by Lightcycler 480
software (Roche) based on a standard curve. Primers used are listed in
Supplementary Table 25. Culture media was collected from the same samples used
for RNA analyses. Following the 12 h insulin/dexamethasone stimulation, secreted
leptin and adiponectin were measured using the Perkin-Elmer AlphaLISA kits for
mouse leptin and adiponectin (according to the manufacturer’s protocol). Not all
samples were included for adiponectin measurement due to the discontinuation of
the AlphaLISA kit by Perkin-Elmer.
Statistics. Each gene knockdown was tested on tissue from 5 to 13 different
mice, as indicated. Control and knockdown samples from each mouse were treated
as matched pairs. Each data point represents the mean of three replicates from a
single mouse. Differences between control and knockdown conditions were
calculated by two-way repeated measures analysis of variance using GraphPad
Prism 6. P-values o0.05 were considered signiﬁcant.
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